ALTA3263 plus cetuximab achieved a 31% objective response rate (ORR) and 94% disease control rate (DCR) in patients with advanced metastatic colorectal cancer (CRC), with responses observed across multiple KRAS mutations ALTA3263 was generally well tolerated as monotherapy and in combination with cetuximab, supporting further evaluation in combination regimens
Late-breaking oral presentation to showcase preliminary safety, tolerability, clinical activity, and pharmacokinetics data of ALTA3263 in monotherapy and in combination with cetuximab
Veteran medical oncologist with a proven track record of advancing cancer therapies from early trials through regulatory approval to lead ongoing clinical development of ALTA2618 and ALTA3263
Alterome Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the development of next-generation, small molecule targeted therapies for the treatment of cancer, today announced that the first patient has been dosed in the Phase 1/1b trial of ALTA3263 in adults with KRAS mutant solid tumors.